CARSGEN
LIVE

Serial Number

79402612

Owner

CARsgen Therapeutics Co., Ltd

Attorney

Adam Bell

Filing Date

Apr 9, 2024

Add to watchlist:

No watchlists yet
View on USPTO

CARSGEN Trademark

Serial Number: 79402612 • Registration: 8054675

CARSGEN is a trademark filed by CARsgen Therapeutics Co., Ltd on April 9, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

CARsgen Therapeutics Co., Ltd

Building 12, No.388, Yindu Road,

Entity Type: 99

Trademark Details

Filing Date

April 9, 2024

Registration Date

December 9, 2025

Published for Opposition

October 21, 2025

Goods & Services

Medical screening; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; human tissue bank services; alternative medicine services; therapy services, namely, medical therapy, medicine therapy, immunotherapy, cell therapy, gene therapy, antibody therapy, antibody-drug conjugate therapy, radiation therapy, chemotherapy, and stem cell therapy; telemedicine services; health care; medical clinic services

Pharmaceutical preparations for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; biological preparations for medical purposes for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; medicinal solutions for injection, namely, medicines for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; biomedicine for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; blood for medical purposes; pre-filled syringes for medical purposes filled with pharmaceutical preparations for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; pharmaceuticals for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; biological tissue cultures for medical purposes; serotherapeutic medicines for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases

Scientific research; scientific laboratory services; research and development of new products for others; technical project studies, namely, conducting scientific feasibility studies; technological research in the field of pharmaceutical studies, biotechnology, medicine, immunotherapy; chemical research; chemistry services, namely, chemist services and chemistry consultation; chemical analysis; medical research; medical and scientific research, namely, conducting clinical trials for others; biological research

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 9, 2026 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jun 20, 2026 FICS
FINAL DISPOSITION PROCESSED
Jun 20, 2026 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 9, 2026 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Feb 5, 2026 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 21, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jan 21, 2026 OPNR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 9, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 9, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 21, 2025 NPUB
PUBLISHED FOR OPPOSITION
Oct 21, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 15, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 23, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 23, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 23, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 23, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 23, 2025 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Apr 4, 2025 GNFN
FINAL REFUSAL E-MAILED
Apr 4, 2025 GNFR
FINAL REFUSAL WRITTEN
Apr 4, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 2, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 2, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 2, 2025 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 1, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Apr 1, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 1, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 1, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 1, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 1, 2025 COAR
REFUSAL PROCESSED BY IB
Nov 17, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 29, 2024 RFCS
REFUSAL PROCESSED BY MPU
Oct 29, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 23, 2024 RFCR
NON-FINAL ACTION WRITTEN
Oct 22, 2024 CNRT
ASSIGNED TO EXAMINER
Oct 22, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 23, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 23, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 22, 2024 REPR